Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AIM2
    (1)
  • CCR
    (2)
  • IL Receptor
    (1)
  • NOD
    (1)
  • RIP kinase
    (2)
  • Others
    (9)
Filter
Search Result
Results for "

thp-1 cell

" in TargetMol Product Catalog
  • Inhibitor Products
    17
    TargetMol | Activity
  • Recombinant Protein
    5
    TargetMol | inventory
  • Peptides Products
    3
    TargetMol | natural
  • Natural Products
    2
    TargetMol | composition
Cell-cell interaction 1
T50083918328-92-4
12-oxo-N-[1-(propan-2-yl)piperidin-4-yl]-6H,7H,8H,9H,10H,12H-azepino[2,1-b]quinazoline-3-carboxamide available as a molecular structural unit, it is used in the synthesis of various compounds.
  • $142
In Stock
Size
QTY
a-Bag Cell Peptide (1-8)
T8322087549-53-9
α-Bag Cell Peptide (1-8) is an NH2-terminal fragment of α-bag cell peptide that inhibits LUQ (left upper quadrant) neurons and the depolarization of bag cells [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
a-Bag Cell Peptide (1-7)
T8322187549-54-0
α-Bag Cell Peptide (1-7) is an amino-terminal fragment of the α-bag cell peptide that possesses the ability to inhibit neurons in the left upper quadrant (LUQ) and prevent the depolarization of the bag cells [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Immune cell migration-IN-1
T820742316683-71-1
Immune cell migration-IN-1 (compound 2) serves as a potent inhibitor of immune cell migration, with potential research applications for mitigating conditions such as dry eye diseases, eczema dermatitis, and psoriasis [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
MLN-3897 TFA
T28072L
MLN-3897 TFA is a potent CCR1 antagonist that inhibits the binding of 125I-MIP-1α to THP-1 cell membranes.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GSK2983559 free acid
T114921579965-12-0In house
GSK2983559 free acid is an effective and selective inhibitor of receptor-interacting protein 2 (RIP2). GSK2983559 free acid shows excellent activity in blocking many proinflammatory cytokine responses in human inflammatory bowel disease explant samples an
  • $44
In Stock
Size
QTY
IL-4-inhibitor-1
T365271332184-63-0In house
IL-4 inhibitor is an inhibitor of IL-4.1It binds to IL-4 with a Kdvalue of 1.8 μM and inhibits IL-4 activity in a cell-based reporter assay (EC50= 1.81 μM). It is selective for IL-4 over IL-13 (EC50= 18.2 μM). IL-4 inhibitor inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes (EC50= 3.1 μM), indicating inhibition of the IL-4-JAK1-STAT6 signaling pathway.
  • $39
In Stock
Size
QTY
MLN-3897
T280721010731-97-1In house
MLN-3897 (CCR1 antagonist 10) is an orally active antagonist of CCR1 with a Ki of 2.3 nM for 125I-MIP-1α binding to THP-1 cell membranes. MLN-3897 inhibits Akt signaling and MM cell survival and proliferation.
  • $1,330
1-2 weeks
Size
QTY
C18 Globotriaosylceramide (d18:1/18:0)
T3743969283-33-6
C18 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from lactosylceramide . It inhibits aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate (PMA; 10008014) when used at a concentration of 1 μM. C18 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. C18 globotriaosylceramide also accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
C16 Globotriaosylceramide (d18:1/16:0)
T36859137896-85-6
C16 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide . C16 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease. C16 globotriaosylceramide is also upregulated in plasma of patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
FSL-1 TFA
T35701
FSL-1 TFA, a toll-like receptor 2/6 (TLR2/6) agonist derived from bacteria, bolsters resistance against experimental HSV-2 infection[1] and stimulates MMP-9 production via the TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
STING Agonist 1a
T38160652142-94-4
STING agonist 1a is an agonist of stimulator of interferon genes (STING).1It induces expression of an IRF-inducible SEAP reporter gene in a cell-based assay (EC50= 16.77 μM). STING agonist 1a (12.5-100 μM) induces expression of IFN-β, IL-6, and chemokine (C-X-C motif) ligand 10 (CXCL10) in THP-1 cells, an effect that can be reversed by STING knockout or the STING inhibitor H-151 . 1.Hou, H., Yang, R., Liu, X., et al.Discovery of triazoloquinoxaline as novel STING agonists via structure-based virtual screeningBioorg. Chem.100103958(2020)
  • $123
35 days
Size
QTY
Euphohelioscopin A
TN559387064-61-7
Euphohelioscopin A, an activator of protein kinase C (PKC), it inhibits proliferation and induces differentiation of the myeloid leukemia cell lines THP-1 and HL-60. Euphohelioscopin A has anti-inflammary activity, it exhibits moderate inhibitory activity
  • $660
Backorder
Size
QTY
NLRP3/AIM2-IN-3
T604421787787-60-3
NLRP3/AIM2-IN-3 is a unique molecule that inhibits NLRP3 and AIM2 inflammasome activation in a species-specific manner. It has an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 is a potent inhibitor of NLRP3 and AIM2 inflammasome-dependent cell lysis with an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 inhibits LPS/nigericin NLRP3/AIM2-IN-3 inhibits LPS/nigericin-stimulated cell lysis in THP-1 macrophages with an IC50 value of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 interferes with the interaction of NLRP3 or AIM2 with the bridging protein ASC, inhibiting oligomerization of ASC.
  • $68
In Stock
Size
QTY
(-)-Pinocembrin
T72742206660-42-6
(-)-Pinocembrin demonstrates anti-mycobacterial activity against Mycobacterium tuberculosis H37Ra, presenting IC 50 values of 1.11 mg/mL in the dormant phase and 1.21 mg/mL in the active phase. Additionally, this compound exhibits significant antiproliferative effects on various cell lines, including THP-1, A549, Panc-1, HeLa, and MCF7, with IC 50 values ranging from 1.88 to 11.00 mg/mL.
  • $1,520
6-8 weeks
Size
QTY
AI-10-47
T90161256094-31-1
AI-10-47 (1H-Benzimidazole, 2-(2-pyridinyl)-6-(trifluoromethoxy)-AI-10-47) is a small molecule inhibitor of CBFβ-RUNX binding(IC50 : 3.2 μM).
  • $76
In Stock
Size
QTY
RIPK2/3-IN-1
T79352
RIPK2/3-IN-1 is a potent inhibitor of both RIPK2 and RIPK3 kinases, exhibiting IC50 values of 3 nM for RIPK2 and 117 nM for RIPK3. Additionally, in a 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay, RIPK2/3-IN-1 demonstrates an IC50 value of 14 ± 4 nM against RIPK2 [1].
  • Inquiry Price
Size
QTY